Parkinson’s disease (PD) is a neurodegenerative disorder that affects the motor systems in early stages, leading to symptoms such as trembling, slowing of movement, and muscle stiffness. The distinct disease mechanism can be modelled in different mouse models of PD. Alpha-synuclein (α-syn) inclusions are the main histopathological hallmark correlating with clinical symptoms of not only PD, but also other synucleinopathies such as dementia with Lewy bodies (DLB), and multiple systems atrophy (MSA). In line, the development and spread of α-syn aggregates plays a key role in the disease pathophysiology. 

InnoSer has extensive preclinical experience with alpha-synuclein seeding mouse models using both PD patient-derived brain extracts and/or recombinant seeds.  Injection of brain extracts from these diseases in the brain of mice closely mimics the structural features of the α-syn aggregates found in patients and allows studying of α-syn spreading as a therapeutic readout. The choice of a specific α-syn seeding model i.e., the brain source or recombinant seed depends on the synucleinopathy of interest.